Back to top
more

Incyte (INCY)

(Real Time Quote from BATS)

$52.99 USD

52.99
1,498,310

+1.31 (2.54%)

Updated Apr 29, 2024 02:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

The headline numbers for Incyte (INCY) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Incyte (INCY) Surpasses Q3 Earnings Estimates

by Zacks Equity Research

Incyte (INCY) delivered earnings and revenue surprises of 0.92% and 5.58%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Drug, Biotech Stocks' Q3 Earnings Due on Oct 31: AMGN, PFE, INCY

by Zacks Equity Research

Let's take a look at three biotech/drug companies, AMGN, PFE and INCY, slated to release quarterly results on Oct 31.

Incyte (INCY) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Higher sales of lead drug Jakafi and incremental sales of newly approved drugs are likely to have boosted Incyte's (INCY) top line during the third quarter of 2023.

Sarepta Therapeutics (SRPT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Incyte (INCY) Stock Plummets 29.6% Year to Date: Here's Why

by Zacks Equity Research

Incyte (INCY) loses 29.6% year-to-date as competition increases for Jakafi and the company suffers pipeline setbacks.

AbbVie's (ABBV) Rinvoq Meets Key Goal in Phase II Vitiligo Study

by Zacks Equity Research

AbbVie (ABBV) meets the primary goal in the phase II study evaluating Rinvoq in the treatment of adult patients with non-segmental vitiligo.

Incyte (INCY) Posts Upbeat Data From Phase II Vitiligo Study

by Zacks Equity Research

Incyte (INCY) announces new positive 52-week data from its mid-stage study of povorcitinib for the treatment of adult patients with extensive nonsegmental vitiligo.

Incyte (INCY) Down on FDA Nod for Another Myelofibrosis Drug

by Zacks Equity Research

Incyte (INCY) declines on potential competition for lead drug Jakafi from Ojjaara for the treatment of intermediate or high-risk myelofibrosis.

Why Is Incyte (INCY) Down 0.7% Since Last Earnings Report?

by Zacks Equity Research

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

MacroGenics' (MGNX) Shares Jump 19% in One Week: Here's Why

by Zacks Equity Research

MacroGenics (MGNX) shares increase after it reported a surge in Q2 earnings per share. A $50-million milestone payment from Sanofi was also triggered last month.

Incyte (INCY) Beats on Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Incyte (INCY) reports impressive Q2 earnings on strong uptake in Jakafi and Opzelura sales. The company raises the bottom end of full-year guidance, setting a new range of $2.58-$2.63 billion.

Compared to Estimates, Incyte (INCY) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Incyte (INCY) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Incyte (INCY) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Incyte (INCY) delivered earnings and revenue surprises of 13.79% and 3.74%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Ahan Chakraborty headshot

Drug, Biotech Stocks' Q2 Earnings Due on Aug 1: PFE, MRK & More

by Ahan Chakraborty

Let's look at five big biotech, pharma companies, PFE, MRK, VRTX, EXEL and INCY, slated to release quarterly results on Aug 1.

Incyte (INCY) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Incyte's (INCY) second-quarter 2023 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.

Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline

by Zacks Equity Research

Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Incyte (INCY) Q2 Earnings Expected to Decline

by Zacks Equity Research

Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 87.50% and 36.58%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Incyte's (INCY) Opzelura Meets Goal in Phase III Pediatric Study

by Zacks Equity Research

Incyte's (INCY) Opzelura (ruxolitinib cream) meets the primary endpoint in a phase III study in children with atopic dermatitis.

New Strong Sell Stocks for June 16th

by Zacks Equity Research

ARCH, EQBK and INCY have been added to the Zacks Rank #5 (Strong Sell) List on June 16, 2023.

Incyte (INCY) Q1 Earnings Miss Estimates, Revenues Up Y/Y

by Zacks Equity Research

Incyte's (INCY) first-quarter 2023 earnings and revenues miss estimates due to higher patient deductibles and inventory challenges.

Incyte (INCY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Incyte (INCY) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Incyte (INCY) delivered earnings and revenue surprises of -56.47% and 7.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights Fomento Economico Mexicano, NextEra Energy, Charter Communications, General Electric and Incyte

by Zacks Equity Research

Fomento Economico Mexicano, NextEra Energy, Charter Communications, General Electric and Incyte are included in this Analyst Blog.